Investor Fact Sheet

Trimel Pharmaceuticals Corporation

Business Description 

Trimel is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.  The Corporation holds a licence for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system (“TriVair™”).  The Corporation is pursuing the development and application of these technologies for therapeutic categories such as (a) male hypogonadism, (b) female orgasmic disorder, and (c) respiratory disorders, which are significant market opportunities in the United States.

The Corporation’s drug delivery technology platforms are intended to create products that are expected to be safer, more effective, easy to use and more practical than in circumstances where competitive products are on the market.  Since the Corporation’s inception, it has focused on the optimization of known high volume pharmaceutical compounds in order to improve their performance and utilization by physicians and patients.

Stock Exchange

Toronto Stock Exchange (TSX)

Stock Symbol


Shares Outstanding 

200.9 Million

 Head Office

2486 Dunwin Drive
Mississauga, Ontario, Canada
L5L 1J9
T: (416) 679-0771
F: (905) 569-1809


Mr. Ian Ihnatowycz

President & Chief Executive Officer

Mr. Tom Rossi

Chief Financial Officer

Mr. Kenneth G. Howling


PricewaterhouseCoopers LLP

Transfer Agent

Equity Financial Trust Company

 Analyst Coverage
E-mail Address
Phone Number

David Novak 

Cormark Securities Inc.  (416) 943-6397
Joseph Walewicz
Laurentian Bank Securities (514) 350-2914
Douglas Miehm  
RBC Capital Markets
(416) 842-7823
Scott Henry
 Roth Capital Partners
(949) 720-7123
Regulatory Filings To access Trimel's SEDAR filings, please click on the following link:

Trimel Pharmaceuticals Corporation SEDAR Profile Page


© 2015 by Trimel Pharmaceuticals Corporation